DE69906568D1 - Behandlung von hämorrhagischem virusfieber mit protein c - Google Patents

Behandlung von hämorrhagischem virusfieber mit protein c

Info

Publication number
DE69906568D1
DE69906568D1 DE69906568T DE69906568T DE69906568D1 DE 69906568 D1 DE69906568 D1 DE 69906568D1 DE 69906568 T DE69906568 T DE 69906568T DE 69906568 T DE69906568 T DE 69906568T DE 69906568 D1 DE69906568 D1 DE 69906568D1
Authority
DE
Germany
Prior art keywords
protein
treatment
virus device
hemorrhagic virus
provides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69906568T
Other languages
English (en)
Other versions
DE69906568T2 (de
Inventor
Jack Fisher
Betty Yan
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cardiome Pharma Corp
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Application granted granted Critical
Publication of DE69906568D1 publication Critical patent/DE69906568D1/de
Publication of DE69906568T2 publication Critical patent/DE69906568T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4866—Protein C (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE69906568T 1998-11-20 1999-11-15 Behandlung von hämorrhagischem virusfieber mit protein c Expired - Lifetime DE69906568T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10915398P 1998-11-20 1998-11-20
US109153P 1998-11-20
PCT/US1999/027074 WO2000030677A1 (en) 1998-11-20 1999-11-15 Method of treating viral hemorrhagic fever

Publications (2)

Publication Number Publication Date
DE69906568D1 true DE69906568D1 (de) 2003-05-08
DE69906568T2 DE69906568T2 (de) 2004-02-12

Family

ID=22326085

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69906568T Expired - Lifetime DE69906568T2 (de) 1998-11-20 1999-11-15 Behandlung von hämorrhagischem virusfieber mit protein c

Country Status (12)

Country Link
US (2) US6270764B1 (de)
EP (1) EP1131091B1 (de)
JP (1) JP2002530353A (de)
CN (1) CN1326356A (de)
AT (1) ATE235915T1 (de)
AU (1) AU2149800A (de)
BR (1) BR9915460A (de)
CA (1) CA2351470A1 (de)
DE (1) DE69906568T2 (de)
ES (1) ES2195655T3 (de)
IL (1) IL142220A0 (de)
WO (1) WO2000030677A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69906568T2 (de) * 1998-11-20 2004-02-12 Eli Lilly And Co., Indianapolis Behandlung von hämorrhagischem virusfieber mit protein c
WO2002024215A2 (en) * 2000-09-18 2002-03-28 Eli Lilly And Company Method for using activated protein c for the treatment of coagulation-associated disorders
KR20040040489A (ko) 2001-10-15 2004-05-12 카이론 코포레이션 조직 인자 경로 억제제（ｔｆｐｉ）의 저용량 투여에 의한패혈증의 치료
US7132398B2 (en) 2003-05-06 2006-11-07 Dendreon Corporation Method of treatment of hemorrhagic disease using a factor VIIa/tissue factor inhibitor
SG150552A1 (en) * 2004-03-17 2009-03-30 Chiron Corp Treatment of severe community-acquired pneumonia by administration of tissue factor pathway inhibitor (tfpi)
WO2007092607A2 (en) * 2006-02-09 2007-08-16 Genetech, Inc. Treatment of hemorrhagic viral infections using a tissue factor inhibitor
AU2016431615A1 (en) * 2016-12-08 2019-06-20 Cellphire, Inc. Compositions and methods for treatment of loss of fluids leading to hypotension and/or hypovolemia
US20200224164A1 (en) 2018-11-30 2020-07-16 Cellphire, Inc. Platelets as delivery agents
EP3886879A4 (de) 2018-11-30 2022-12-07 Cellphire Inc. Thrombozyten als freisetzungsmittel
WO2020227149A1 (en) 2019-05-03 2020-11-12 Cellphire, Inc. Materials and methods for producing blood products
EP4013496A4 (de) 2019-08-16 2023-10-18 Cellphire Inc. Thrombosomen als mittel zur aufhebung der thrombozytenaggregationshemmenden wirkung
WO2021158622A1 (en) 2020-02-04 2021-08-12 Cellphire, Inc. Anti-fibrinolytic loaded platelets

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4775624A (en) 1985-02-08 1988-10-04 Eli Lilly And Company Vectors and compounds for expression of human protein C
US5516650A (en) 1985-06-27 1996-05-14 Zymogenetics, Inc. Production of activated protein C
US5550036A (en) 1986-04-09 1996-08-27 Eli Lilly And Company Method for co-amplification of human protein C genes in human cells
US4992373A (en) 1987-12-04 1991-02-12 Eli Lilly And Company Vectors and compounds for direct expression of activated human protein C
US4981952A (en) 1988-10-04 1991-01-01 Eli Lilly And Company Method for the purification of vitamin K-dependent proteins
IL97312A (en) 1990-02-23 1999-01-26 Lilly Co Eli A method of generating a polypeptide in an eukaryotic vector AND recombinant surrogate cell containing an enhanced transcriptional control unit based on the primary late adenovirus coefficient
US5506134A (en) * 1990-10-22 1996-04-09 Corvas International, Inc. Hypridoma and monoclonal antibody which inhibits blood coagulation tissue factor/factor VIIa complex
AT402262B (de) 1991-06-20 1997-03-25 Immuno Ag Arzneimittel enthaltend aktiviertes protein c
MY110664A (en) 1992-05-21 1999-01-30 Lilly Co Eli Protein c derivatives
WO1997020043A1 (en) 1995-11-30 1997-06-05 Zymogenetics, Inc. Protein c production in transgenic animals
EA002149B1 (ru) * 1997-04-28 2001-12-24 Эли Лилли Энд Компани Улучшенные способы приготовления активированного белка с
DE69906568T2 (de) * 1998-11-20 2004-02-12 Eli Lilly And Co., Indianapolis Behandlung von hämorrhagischem virusfieber mit protein c
AU4188500A (en) * 1999-04-30 2000-11-17 Eli Lilly And Company Protein c derivatives

Also Published As

Publication number Publication date
EP1131091A1 (de) 2001-09-12
AU2149800A (en) 2000-06-13
US20010028880A1 (en) 2001-10-11
CN1326356A (zh) 2001-12-12
IL142220A0 (en) 2002-03-10
WO2000030677A1 (en) 2000-06-02
JP2002530353A (ja) 2002-09-17
EP1131091B1 (de) 2003-04-02
BR9915460A (pt) 2001-07-17
DE69906568T2 (de) 2004-02-12
ATE235915T1 (de) 2003-04-15
CA2351470A1 (en) 2000-06-02
US6270764B1 (en) 2001-08-07
US6767539B2 (en) 2004-07-27
ES2195655T3 (es) 2003-12-01

Similar Documents

Publication Publication Date Title
ATE234092T1 (de) 2-alkylpyrrolidine
DE69925256D1 (de) Trisubstituierte 1,3,5-triazine derivate zur behandlung von hiv infektionen
DE60022692D1 (de) (S,S)-Reboxetin zur Behandlung von Migränekopfschmerzen
DE68907909D1 (de) Praeparat zur behandlung von erektionsstoerungen.
DE58905201D1 (de) Mittel zur behandlung des parkinson-syndroms.
DE69906568D1 (de) Behandlung von hämorrhagischem virusfieber mit protein c
NO903449D0 (no) Fremgangsmaate for aa behandle underjordiske formasjoner.
ATE218857T1 (de) Verwendung von gabapentin und seine derivate in der behandlung von manie und bipolare störungen
DE69200684D1 (de) Vorrichtung zur thermischen Behandlung von laufenden Garnen.
ES2079068T3 (es) 2-amino-6-fenil-4h-piran-4-onas antiateroscleroticas y antitromboticas.
ATE139226T1 (de) Aminosulfonylharnstoff-acat-inhibitoren
ES2113910T3 (es) Procedimiento para la preparacion de un concentrado de trombina asegurado contra virus.
ES2135722T3 (es) 1,5-benzodiacepinas 5-heterociclicas moduladoras de la cck o de la gastrina.
RU94041028A (ru) Применение производных мелатонина для лечения десинхронизационных нарушений, фармацевтическая композиция
ATE139698T1 (de) Mittel zur behandlung chronischer ermüdungserscheinungen
ATE215084T1 (de) Imidazopyridin-azolidinone
JPS5395961A (en) Tetrahydrophthalimide derivatives process for their preparation and herbicides containing the same
ATE129895T1 (de) Behandlung von pulmonarer disfunktion mit 15-keto-prostaglandin-derivaten.
DE69905489D1 (de) Protein c zur behandlung von sichelzellanämie und thalassämie
BR9915317A (pt) Método de tratar trombocitopenia induzida por heparina
DE3378979D1 (en) 1-acyl-3-pyridylmethylguanidines and their use as antihypertensive agents
ES2061775T3 (es) Derivados de estrobirulina, su obtencion y empleo.
DK0952982T3 (da) Hidtil ukendte hepatitis B inhibitorer
ATE264113T1 (de) Verwendung von protein c zur behandlung von thrombozytopenischer purpura und hämolytisches urämisches syndrom
DE69006964D1 (de) Behandlung von Hyperlipidemia mit 15-keto-Prostaglandin-Verbindungen.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: CARDIOME PHARMA CORP., VANCOUVER, CA

8328 Change in the person/name/address of the agent

Representative=s name: KROHER, STROBEL RECHTS- UND PATENTANWAELTE, 80336

8328 Change in the person/name/address of the agent

Representative=s name: DR. SCHOEN & PARTNER, 80336 MUENCHEN